IRD
BEARISHAt a glance
Key valuation, profitability, growth, and risk metrics.
AI Analysis
AI-powered fundamental assessment
Key Strengths
Key Risks
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Ref P/E, PEG, Graham Number
- P/B of 24.36 is unsustainable
- P/S of 26.86 is extreme for a company with shrinking revenue
- No Graham Number available due to lack of positive earnings
Ref Growth rates
- High analyst target price
- Negative YoY revenue growth (-10.20%)
- Negative Q/Q revenue growth (-10.16%)
Ref Historical trends
- Recent price appreciation
- Average earnings surprise of -41.38% over last 4 quarters
- History of massive EPS misses
Ref Altman Z-Score, Piotroski F-Score
- High current ratio
- Low debt
- Piotroski F-Score 1/9 indicates critical weakness
- ROE of -242.41% shows massive capital erosion
Ref Yield, Payout
- No dividend paid
- Zero dividend strength
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for IRD and closest competitors.
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
IRD
Opus Genetics, Inc.
Primary
|
+2.3% | -0.9% | +654.9% | +173.5% | +7.0% | +17.8% |
|
BNR
Burning Rock Biotech Limited
Peer
|
-89.9% | +6.9% | +414.2% | +415.7% | +65.3% | +9.6% |
|
AKBA
Akebia Therapeutics, Inc.
Peer
|
-59.4% | +113.8% | -13.6% | -50.5% | -5.8% | +15.0% |
|
ENTA
Enanta Pharmaceuticals, Inc.
Peer
|
-71.8% | -64.9% | +208.7% | +21.9% | -0.9% | +6.2% |
|
AGL
agilon health, inc.
Peer
|
-96.8% | -95.0% | -73.1% | -51.9% | +41.4% | -2.8% |
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Valuation Metrics
Key valuation ratios and pricing indicators
Profitability
Profit margins and return metrics
Growth
Revenue and earnings growth rates
Financial Health
Balance sheet strength and liquidity metrics
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Quarterly Earnings History
EPS performance vs analyst estimates
Healthcare Sector Comparison
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
IRD
Opus Genetics, Inc.
|
BEARISH | $381.36M | - | -242.4% | -% | $5.36 | |
|
BNR
Burning Rock Biotech Limited
|
BEARISH | $377.58M | - | -20.2% | -22.5% | $35.07 | Compare |
|
AKBA
Akebia Therapeutics, Inc.
|
BEARISH | $391.1M | - | -% | -2.3% | $1.46 | Compare |
|
ENTA
Enanta Pharmaceuticals, Inc.
|
BEARISH | $399.6M | - | -60.0% | -106.8% | $13.77 | Compare |
|
AGL
agilon health, inc.
|
BEARISH | $410.85M | - | -73.3% | -5.2% | $0.99 | Compare |
Wall Street Analysts
Professional analyst ratings and price targets
Past News Coverage
Recent headlines mentioning IRD from our newsroom.